Evidence map›Paper›PMID 26282919›Full record

ArticleEMBO molecular medicine2015

AID-expressing epithelium is protected from oncogenic transformation by an NKG2D surveillance pathway.

Arantxa Pérez-García, Pablo Pérez-Durán, Thomas Wossning, Isora V Sernandez, Sonia M Mur, Marta Cañamero, Francisco X Real, Almudena R Ramiro

Open access · goldAbstract read
In one paragraph

Article in EMBO molecular medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Arantxa Pérez-GarcíaB Cell Biology Lab, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Pablo Pérez-DuránB Cell Biology Lab, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Thomas WossningB Cell Biology Lab, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Isora V SernandezB Cell Biology Lab, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Sonia M MurB Cell Biology Lab, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Marta CañameroRoche Diagnostics GmbH, Penzberg, Germany.
Francisco X RealEpithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Almudena R RamiroB Cell Biology Lab, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain aramiro@cnic.es.
Spanish National Centre for Cardiovascular Research · ESRoche Pharma AG (Germany) · DESpanish National Cancer Research Centre · ES

Funding

European Research Council 207844
6 · The paper itself

Abstract

Activation-induced deaminase (AID) initiates secondary antibody diversification in germinal center B cells, giving rise to higher affinity antibodies through somatic hypermutation (SHM) or to isotype-switched antibodies through class switch recombination (CSR). SHM and CSR are triggered by AID-mediated deamination of cytosines in immunoglobulin genes. Importantly, AID activity in B cells is not restricted to Ig loci and can promote mutations and pro-lymphomagenic translocations, establishing a direct oncogenic mechanism for germinal center-derived neoplasias. AID is also expressed in response to inflammatory cues in epithelial cells, raising the possibility that AID mutagenic activity might drive carcinoma development. We directly tested this hypothesis by generating conditional knock-in mouse models for AID overexpression in colon and pancreas epithelium. AID overexpression alone was not sufficient to promote epithelial cell neoplasia in these tissues, in spite of displaying mutagenic and genotoxic activity. Instead, we found that heterologous AID expression in pancreas promotes the expression of NKG2D ligands, the recruitment of CD8(+) T cells, and the induction of epithelial cell death. Our results indicate that AID oncogenic potential in epithelial cells can be neutralized by immunosurveillance protective mechanisms.

Indexed as

AICDA (Activation-Induced Cytidine Deaminase)AnimalsCD8-Positive T-LymphocytesCell DeathCell Transformation, NeoplasticColonCytidine DeaminaseCytotoxicity Tests, ImmunologicEpitheliumMiceMice, TransgenicNK Cell Lectin-Like Receptor Subfamily KPancreasAICDA (Activation-Induced Cytidine Deaminase)Cytidine DeaminaseKlrk1 protein, mouseNK Cell Lectin-Like Receptor Subfamily Kactivation‐induced deaminasecancerepitheliumNKG2Dpancreas

Identifiers

PMID26282919
PMCPMC4604686
OpenAlexW2155246062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.